December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pyxis Oncology, Inc. - Common Stock (NQ:PYXS)

2.550 +0.080 (+3.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pyxis Oncology, Inc. - Common Stock

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
 
Via Benzinga
Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
 
Via Benzinga
Pyxis Oncology: Q4 Earnings Insights
 
Via Benzinga
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer. 
Via Benzinga
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and a $13 price target, with upcoming clinical trial results. 
Via Benzinga
PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024
PYXS stock results show that Pyxis Oncology missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024
PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. 
Via Benzinga
Topics Stocks
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
Via Benzinga
3 Biotech Stocks to Buy on the Dip: March 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
Via InvestorPlace
Why FedEx Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of FedEx Corporation (NYSE: FDX) rose sharply in today’s pre-market trading after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion 
Via Benzinga
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. 
Via Benzinga
PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023
PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst
RBC Capital Markets has initiated coverage on Pyxis Oncology Inc (NASDAQ: PYXS) with an Outperform rating and a  
Via Benzinga
Small SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023
 
Via Benzinga
Pyxis Oncology Bolsters Oncology Portfolio Through $16M Apexigen Acquisition
Pyxis Oncology (NASDAQ:PYXS) has announced an acquisition of Apexigen (NASDAQ:APGN) that is expected to be completed in the second half of 2023. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
 
Via Benzinga
Why Is Apexigen (APGN) Stock Up 31% Today?
Apexigen (APGN) stock is rising higher on Wednesday following news of a $16 million acquisition deal with Pyxis Oncology (PYXS). 
Via InvestorPlace
Why Chicken Soup For The Soul Entertainment Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Gainers RiceBran Technologies (NASDAQ: RIBT) gained 43.1% to $1.33 in pre-market trading after gaining 3% on Tuesday. 
Via Benzinga
Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.